Introduction
The flavivius family, of which yellow fever virus (YFV) is the prototype, consists of approximately 65 enveloped, positive strand RNA viruses which are found primarily in tropical areas, causing a wide variety of febrile illnesses marked by hepatitis, encephalitis or haemorrhage. Although a safe and effective live attenuated vaccine has been available for yellow fever for 50 years (Theiler & Smith, 1937) , attempts to produce similar vaccines against other flaviviruses using conventional methods have met with limited success. New knowledge of flavivirus genomic structure suggests application of recombinant techniques to the production of future vaccines against these viruses.
A single open reading frame of about 10-5 kb encodes all known flavivirus proteins and i~ arranged as follows: 5' C-prM-E-NS 1-NS2a-NS2b-NS3-ns4a-ns4b-NS5 3' (Rice et al., 1985 (Rice et al., , 1986 . Virion structural proteins (capsid, prematrix and envelope) are encoded at the 5' end, followed by non-structural (NS) proteins encoded by the remaining gene segment.
Although neutralizing antibody directed against the virion envelope glycoprotein, E, has long been associated with protection against these viruses, the recent demonstration of protection by immunization with the nonstructural glycoprotein NS 1 has stimulated interest in the flavivirus NS proteins as vaccine components (Gibson et al., 1988) . Such protection, originally demonstrated by passive immunization of mice with anti-NS 1 monoclonal antibodies (Schlesinger et al., 1985; Gould et al., 1986) or active immunization with NS1 protein purified from flavivirus-infected cells (Schlesinger et al., 1985 (Schlesinger et al., , 1986 , has subsequently been confirmed with recombinant NS 1 proteins (Cane & Gould, 1988; Zhang et al., 1988; Bray et al., 1989) as well. However, it is of interest that the degree of protection has varied widely with the choice of expression vector; immunization with vaccinia virus expressing dengue-4 virus NS 1 conferred solid immunity , whereas YFV NS1 produced as a flgalactosidase fusion protein in Escherichia coli was only partially protective (Cane & Gould, 1988) and Japanese encephalitis virus NS1 produced by a recombinant baculovirus vector conferred no protection (McCown et al., 1990) .
To initiate further studies into the role of NS proteins in the protective immune response to YFV infection, we inserted YFV cDNA encoding a region consisting of the C terminus of E to the N terminus of NS3 (nucleotides 2030 to 4940; Rice et al., 1985) into a vaccinia virus vector. The recombinant NSI which was produced shared many of the properties of native YFV NS1 0000-9513 © 1990 SGM including cell surface expression and secretion and elicitation of cytolytic antibodies, as well as the capacity to protect mice against lethal intracerebral challenge with 17D YFV after active immunization with the recombinant virus.
Methods
Cloning and expression. A YFV-specific cDNA (clone 10III), kindly provided by Charles Rice (Washington University School of Medicine, St Louis, Mo., U.S.A.), was restricted with HpaI and BgllI. The resulting 2.9 kb fragment (nucleotides 2030 to 4940) was isolated by agarose gel electrophoresis and cloned into the vaccinia virus recombination vector pUV 1 (gift of Bernard Moss, National Institute of Allergy and Infectious Diseases, Bethesda, Md., U.S.A.) which had been prepared by cutting with PstI, creating a blunt end with T4 DNA polymerase and finally cutting with BamHI. CV1 cells were infected with wild-type vaccinia virus (WR strain) at a multiplicity of 0.05 p.f.u./cell, incubated for 1 h at room temperature and then cotransfected with 15 gg of insert-containing pUV1 DNA in the presence of CaC12. Insertion of the YFV genes into the thymidine kinase (TK) gene of the vaccinia virus genome was by homologous recombination (Chakrabarti et al., 1985) . At 48 h post-transfection, cells were harvested and virus was released by freezing, thawing and sonication. Recombinants were plaque-purified three times on a human fibroblast cell line (HuTK-) lacking functional TK in the presence of 25 gg/ml 5-bromo-2'-deoxyruidine (BUdR; Sigma) which selects for TK-virus. Due to the particular construction of the pUV1 vector, recombinants expressed fl-galactosidase under the control of the vaccinia virus p7.5K early-late promoter, and therefore formed blue plaques in the presence of the chromogenic substrate 5-bromo-4-chloro-3-indolyl-fl-D-galactosidase (X-Gal; BRL) (Chakrabarti et al., 1985) . YFV gene expression was under control of the vaccinia virus pl 1K late promoter.
Fluorescent antibody assay. Cells grown on 23 cm 2 glass coverslips (Erie Scientific Company) were infected at a muiltiplicity of about 0.5 p.f.u./cell with recombinant vaccinia virus bearing the gene for YFV NS1 protein. At 24 or 48 h post-infection, the monolayers were washed with phosphate-buffered saline (PBS) pH 7.4, and the cells were fixed with 4~ neutral paraformaldehyde (Sigma) at room temperature for 5 min or left unfixed. The monolayers were then washed with PBS and incubated with an NS 1-specific monoclonal antibody, 1 A5 (Schlesinger et al., 1983 (Schlesinger et al., , 1985 , diluted 1:100 in PBS containing 25~ foetal calf serum for 1 h at room temperature. After washing extensively with PBS, the cells were incubated with a 1 : 20 dilution of goat anti-mouse immunoglobulin conjugated to fluorescein isothiocyanate (FITC) (Boehringer Mannheim). After extensive washing with PBS, the coverslips were mounted in glycerol :PBS (9:1) and the stained cells were photographed using a Leitz fluorescence microscope with attached Nikon camera.
Immunoprecipitation andpolyacrylamide gels. Cells in six-well plates (Nunc) were infected with YFV 17D, recombinant or wild-type vaccinia virus at a multiplicity of infection of approximately 0.5 p.f.u./cell. After a 1 h adsorption, cells were fed with 2 ml Eagle's minimal essential medium (Gibco). At 24 to 48 h after infection, labelling of viral proteins was carried out by addition of 50 gCi/ml [35S]methionine (New England Nuclear) in medium containing 1/20 the normal amount of methionine. After a 4 h labelling period, cells and culture supernatant media were harvested separately. Cells were washed once with medium and lysed by resuspending in immunoprecipitation buffer (0-15 ~i-NaC1, 50 mM-Tris-HC1 pH 8, 1 ~ Nonidet P-40, 1 ~ Triton X-100 and 0-2~ SDS). Antibody was added to a dilution of 1 : 100 and incubated for at least 18 h at 4 °C. Immunoprecipitates were captured on staphylococcal Protein A beads (Bio-Rad) and, after washing, removed from the beads by addition of disruption buffer (Laemmli, 1970) . The samples were then either boiled for 5 rain or left unboiled. They were electrophoresed on 12.5~ polyacrylamide gels containing 0.1% SDS, and the gel was then dried and exposed to Kodak XAR X-ray film for 1 week.
Cytolytic assay. Sera from immunized mice were tested for anti-NS1 specific cytolytic activity by incubating the sera and rabbit serum complement with YFV-infected, 51Cr-loaded SW 13 cells as previously, described (Schlesinger et al., 1985) .
Mouse protection assay. BALB/c mice (Charles River) were immunized by intraperitoneal (i.p.) injection at 3 weeks of age with l06 p.f.u. of recombinant vaccinia virus bearing the YFV NS1 gene and including a small part of E, all of NS2a, NS2b and part of NS3 (nucleotides 2030 to 4940). A second group of mice was immunized i.p. with 106 p.f.u, of live YFV 17D as a positive control and a third group was immunized i.p. with 105 p.f.u, of wild-type vaccinia virus as a negative control. Serum samples were obtained from immunized mice by tail-nick 1 day prior to YFV challenge. At 3 weeks postimmunization, mice were challenged with 4 x 105 p.f.u, ofYFV 17D injected intracerebrally (i.c.). Mice were observed daily for morbidity and mortality.
Statistics. Results of cytolytic assays were plotted on scatter plots. Probability (P) values were calculated by the chi-square test or a test for the difference between two group means by pooled estimate of variance.
Results

Comparison of recombinant and native YFV NS1
Synthesis of NS1 protein in recombinant vaccinia virusand 17D YFV-infected cells was compared. Both made protein which was immunoprecipitated by NSl-specific monoclonal antibody 1A5. When electrophoresed after boiling and reduction with 2-mercaptoethanol, both cellassociated proteins had an Mr of about 45K (Fig. l, lanes  1 and 2) . Electrophoresis of these proteins without boiling and reduction resulted in high Mr bands in addition to a band of about 40K, which is consistent with unreduced NS1 monomer (Fig. 1, lanes 3 and 4) . The presence of high Mr bands (a clear doublet with 17D YF NS 1 and predominantly one band with the recombinant) suggests that both recombinant and native YFV NS1 proteins formed similar oligomers or polymers which may represent a native form of flavivirus NS1 (Winkler et al., 1988) . Additionally, extracellular NS1 was detected in cell-free culture supernatants from recombinant vaccinia virus-and 17D YFV-infected cells (Fig. l,  lanes 5 and 6) . Unboiled, the extracellular NS1 from both sources migrated as an oligomer (results not shown). additional bands of about 80K, 63K, 35K and 25K (Fig.  1, lane 7) . The relationship of these bands to the Cterminal fragment of E, NS2a and NS2b, which are also encoded within the expressed polygenic region, is not known. To determine whether NS1 was expressed at the surface of r e c o m b i n a n t vaccinia virus-infected cells, viable or formalin-fixed cells were i n c u b a t e d with monclonal antibody 1A5, followed by F I T C -l a b e l l e d goat anti-mouse I g G (Fig. 2) . U n d e r these conditions cells are i m p e r m e a b l e to i m m u n o g l o b u l i n p e n e t r a t i o n and showed only bright NSl-specific surface fluorescence. A similar pattern of fluorescence was observed with 17D YFV-infected cells. R e c o m b i n a n t or natural YFV-infected cells made permeable by acetone fixation exhibited strong intracytoplasmic fluorescence (results not shown). We have previously shown that a n t i b o d y to NS1 can sensitize Y F V -i n f e c t e d cells to complementmediated i m m u n e cytolysis a n d have suggested that this is indicative of plasma m e m b r a n e -a s s o c i a t i o n of the protein (Schlesinger et al., 1990) . To determine whether r e c o m b i n a n t -i n f e c t e d cells are similarly susceptible to 
Protection of mice against fatal YFV encephalitis by immunization with the vaccinia virus recombinant
The capacity of recombinant vaccinia virus immunization to protect mice against lethal i.c. challenge with 17D YFV was tested. Three-week-old BALB/c mice were immunized with a single i.p. dose of recombinant vaccinia virus, wild-type parent vaccinia virus or live 17D YFV, followed 3 weeks later by i.c. challenge with a uniformly lethal dose (4 x 10 s p.f.u.) of 17D YFV. Survival in each group is shown in Fig. 3 . In the first experiment (Fig. 3a) , 10 of the 20 recombinantimmunized mice, but none of the control wild-type vaccinia virus-immunized mice, survived (P < 0-001).
No illness was observed among 17D YFV-immunized mice. However, 6 to 7 days after challenge, all recombinant-immunized mice had ruffled fur and slowed movement which in some progressed to permanent hind leg paralysis. Of the mice which ultimately survived, most appeared to have completely recovered. In a similar experiment (Fig. 3b ) mice were immunized with the recombinant or wild-type vaccinia virus and then bled immediately before i.c. challenge. Seven of 11 recombinant-immunized mice survived the challenge (prechallenge bleeding resulted in one death) but none of those immunized with wild-type vaccinia virus survived (P < o.oo4).
To determine whether a correlation between cytolytic antibody activity and survival exists, sera obtained from recombinant-immunized mice immediately before challenge were tested individually for complement-mediated lytic activity against s 1Cr-labelled 17D YFV or wild-type vaccinia virus-infected cells. Sera from all surviving mice exhibited cytolytic activity. Two of the four recombinant-immunized mice which died after challenge had no detectable prechallenge cytolytic or other antibody to 17D YFV or vaccinia virus and thus no evidence of having been vaccinated. Therefore, they were not included in the analysis, the results of which are shown in Fig. 4 . Mean YFV-specific cytolytic activity was higher among surviving mice (21 ~ compared to 10~) but this difference was not statistically significant (P = 0-1), nor was there an apparent correlation between vaccinia virus-specific cytolytic activity and survival. Since the recombinant vaccinia virus encoded 141 amino acids of the C terminus of E (representing about 20% of the protein), we tested mice immunized at 3 weeks of age, and boosted at 6 weeks, for YFVneutralizing antibody by a plaque reduction (PRNT50) assay. No YFV-neutralizing antibody was detected at a 1/10 dilution of serum.
Discussion
The recent demonstration of a protective immune response to the flavivirus NS glycoprotein NS1 suggests its incorporation into possible future recombinant flavivirus vaccines (Schlesinger et al., 1986; Gibson et al., 1988) . To study further the role of viral NS proteins in host defence, YFV cDNA encoding the C terminus of the E protein to the N terminus of NS3 protein (nucleotides 2030 to 4940) was cloned into vaccinia virus and physical and antigenic properties of the NS1 moiety were studied.
Recombinant-and YFV-specified NSI were similar with respect to Mr, cell surface expression and secretion into the culture medium, suggesting that the processing of the recombinant polyprotein segment and that of natural YFV were similar. Correct proteolytic processing of NS1 of another flavivirus, dengue-4, has been shown to require an N-terminal hydrophobic signal peptide, derived from the preceding E glycoprotein, and a Cterminal flanking NS2a protein , both of which are present in this construct. Additionally, both recombinant and native YFV NS1 formed heatlabile polymers providing further evidence of close structural similarity. However, less efficient lysis of recombinant-infected cells by anti-NS1 monoclonal antibody and complement suggests reduced accumulation of NS1 on recombinant-infected cells or, alternatively, some subtle alteration in form. Mice immunized with the present recombinant produced antibody which sensitized 17D YFV-or vaccinia virus-infected cells to complement-mediated lysis and were thus partially protected against lethal i.c. challenge. Current knowledge indicates that only cell surface NSI subserves such cytolytic activity, making it likely that the NSI component of this recombinant accounted for the production of lytic antibody. As a group, surviving mice exhibited greater pre-challenge serum lytic activity than nonsurvivors, but the difference was not statistically significant in this experiment. Although the mechanism of protection provided by NS 1 vaccination is not known with certainty, the capacity of complement-fixing cytolytic anti-NS1 antibody to retard YFV spread in tissue culture (Schlesinger et al., 1990) and the consistent finding of complement-fixing cytolytic activity after protective NS1 immunization (Schlesinger et al., 1986 (Schlesinger et al., , 1987 , strongly suggests a role for immune recognition of cell surface NS1. In this regard it is of interest that recent studies employing cells infected with vaccinia recombinants expressing dengue-4 virus proteins show that NS1 is a target for antibody and complement (J. J. Schlesinger, B. Falgout & C.-J. Lai, unpublished results) but not cytotoxic T lymphocytes (Bukowski et al., 1989) .
In the present study we cannot rule out immune recognition of NS proteins NS2a or NS2b in the protective response to vaccination. Observations with vaccinia virus recombinants expressing dengue-4 virus NS1 suggested that at least part of the flanking NS2a sequence was required for optimal protection of mice (B. Falgout, personal communication) .
Reported variability in the degree of protection conferred by immunization with different NS1 preparations encourages further study of sequence and other physical properties of recombinant NSI that might affect flavivirus vaccine formulation. 
